Distribution and resistance of pathogens in liver transplant recipients with Acinetobacter baumannii infection

Figures & data

Table 1 Demographic, laboratory, and clinical characteristics of 17 liver recipients with Acinetobacter baumannii infection

Characteristic	Value
Age, mean ± SD years	49.7±8.6
Male sex, n (%)	11 (64.7)
Temperature ≥38°C, n (%)	8 (47.1)
Nosocomial origin, n (%)	16 (94.1)
Inappropriate antimicrobial use, n (%)	7 (41.2)
Septic shock, n (%)	5 (29.4)
Site of infection, n (%)
Lung	4 (23.5)
Intra-abdominal/biliary tract	4 (23.5)
Blood	3 (17.6)
Multiple culture-positive sites	6 (35.3)
Time of infection onset, n (%)
<2 weeks post-transplant	12 (70.6)
≥2 weeks post-transplant	5 (29.4)
Induction therapy, n (%)
Yes	1 (5.9)
No	16 (94.1)
Acute rejection prior to infection, n (%)
Yes	1 (5.9)
No	16 (94.1)
Reoperation, n (%)
Yes	4 (23.5)
No	13 (76.5)
Laboratory variables from blood, n (%)
Platelet count <50,000/mm^3	12 (70.6)
Lymphocyte count <300/mm^3	3 (17.6)
Albumin <30 g/L	4 (23.5)
WBC count >15,000/mm^3	7 (41.2)
Creatinine >1.5 mg/dL	9 (52.9)
Related mortality, n (%)	8 (47.1)

Abbreviations: SD, standard deviation; WBC, white blood cell.

Table 2 Resistance of Acinetobacter baumannii to 12 antibiotics according to site of infection (n, %)

Antimicrobial drug	Blood (7)	Lung (8)	Intra-abdominal/biliary duct (8)	Urinary tract (1)	Cases of total drug resistance (n)
MEM	3 (42.9)	8 (100)	6 (75)	1 (100)	18 (75)
TZP	3 (42.9)	8 (100)	6 (75)	1 (100)	18 (75)
CAZ	4 (57.1)	7 (87.5)	6 (75)	1 (100)	18 (75)
FEP	3 (42.9)	8 (100)	6 (75)	1 (100)	18 (75)
CXM	4 (57.1)	8 (100)	7 (87.5)	1 (100)	20 (83.3)
CZO	5 (71.4)	8 (100)	7 (87.5)	1 (100)	21 (87.5)
AN	5 (71.4)	6 (75)	4 (50)	1 (100)	16 (66.7)
LVF	3 (42.9)	5 (62.5)	6 (75)	1 (100)	15 (62.5)
TGC	0 (0)	0 (0)	1 (12.5)	0 (0)	1 (4.2)
SXT	3 (42.9)	7 (87.5)	5 (62.5)	1 (100)	16 (66.7)
CFS	1 (14.3)	6 (75)	4 (50)	0 (0)	11 (45.8)
ATM	4 (57.1)	8 (100)	6 (75)	1 (100)	19 (79.2)

Abbreviations: MEM, meropenem; TZP, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; CXM, cefuroxime; CZO, cefazolin; AN, amikacin; LVF, levofloxacin; TGC, tigecycline; SXT, trimethoprim-sulfamethoxazole; CFS, cefoperazone-sulbactam; ATM, aztreonam.